Flexion Therapeutics Inc represents values of patient-centricity, innovation, and commitment to improving the lives of individuals with musculoskeletal conditions. The company focuses on developing and commercializing novel, long-acting therapies to provide effective pain relief and functional improvements. Flexion Therapeutics Inc believes in putting patients first by addressing their unmet needs and enhancing their quality of life. With a strong corporate philosophy centered on scientific rigor and collaboration, the company strives to advance the field of musculoskeletal medicine through research and development efforts. Flexion Therapeutics Inc aims to empower patients and healthcare providers with innovative treatment options, making significant contributions to the healthcare industry.

Flexion Therapeutics Inc primarily operates in the United States.

Flexion Therapeutics Inc has achieved several significant milestones. Firstly, the company developed and gained FDA approval for their innovative product, Zilretta, a long-acting steroid for osteoarthritis knee pain. This milestone marked a major breakthrough in providing a non-opioid pain management option for patients. Additionally, Flexion Therapeutics Inc has successfully launched Zilretta in the market, contributing to the company's growth and revenue. Furthermore, the company continues to invest in research and development to expand their product portfolio, aiming to address unmet medical needs in the field of musculoskeletal disease. Overall, Flexion Therapeutics Inc has made remarkable strides in developing effective treatments for patients suffering from joint-related pain.

Flexion Therapeutics Inc is a pharmaceutical company headquartered in Burlington, Massachusetts. Established in 2007, the company specializes in developing and commercializing novel, local therapies for the treatment of musculoskeletal conditions, such as osteoarthritis. Flexion Therapeutics Inc aims to provide innovative solutions to enhance patient outcomes and improve their quality of life. Through extensive research and development efforts, the company has successfully brought a range of therapies to market, including ZILRETTA®, an extended-release corticosteroid injection for osteoarthritis knee pain. Flexion Therapeutics Inc continues to expand and develop groundbreaking treatments for the growing number of individuals affected by musculoskeletal conditions.

The main competitors of Flexion Therapeutics Inc in the market include other pharmaceutical companies with a focus on musculoskeletal disorders and pain management. Some notable competitors in this space are Pfizer Inc, Eli Lilly and Company, Johnson & Johnson, and AbbVie Inc. These companies also operate in the development and commercialization of innovative treatments for chronic pain and musculoskeletal conditions. Competitor analysis helps investors understand the competitive landscape and market positioning of Flexion Therapeutics Inc.

Flexion Therapeutics Inc is primarily active in the pharmaceutical industry. This company specializes in the development and commercialization of novel, non-opioid pain therapies for patients with musculoskeletal conditions. With its focus on researching, creating, and delivering innovative solutions, Flexion Therapeutics Inc aims to address the unmet medical needs of individuals suffering from chronic pain. By leveraging its expertise and advanced technologies, the company strives to enhance patients' quality of life and provide effective alternatives to opioid-based treatments. Flexion Therapeutics Inc is committed to advancing healthcare and making a positive impact in the pharmaceutical sector.

Flexion Therapeutics Inc. is a biopharmaceutical company specializing in the development and commercialization of novel therapies for musculoskeletal conditions. They focus on creating innovative treatments for patients with joint-related diseases and manage the pain associated with these conditions. Flexion's business model revolves around acquiring promising drug candidates, conducting extensive research and development, obtaining regulatory approvals, and bringing effective and safe treatments to market. By harnessing their expertise in drug development and understanding the needs of patients, Flexion aims to improve the quality of life for individuals suffering from musculoskeletal disorders.

De Flexion Therapeutics K/W is -8,31.

De Flexion Therapeutics KUV is 1,39.

De AlleAktien Kwaliteitsscore voor Flexion Therapeutics is 4/10.

De verwachte Flexion Therapeutics omzet is 294,55 mln. USD.

De verwachte Flexion Therapeutics winst is -49,37 mln. USD.

Flexion Therapeutics Inc is an American biotechnology company that develops and produces innovative medications in pain therapy. The company was founded in 2007 and is based in Burlington, Massachusetts. Flexion Therapeutics specializes in the research and development of drugs targeting the treatment of osteoarthritis and other pain conditions. Flexion Therapeutics has three main areas of business: research and development, production, and distribution. In research and development, the company focuses on the discovery and optimization of new compounds that specifically relieve pain and improve joint mobility. The company has an experienced team of scientists and researchers who oversee and optimize the compound development process. In production, Flexion Therapeutics utilizes cutting-edge technologies to manufacture high-quality products aimed at pain treatment. The company collaborates closely with external manufacturers to produce its products, which are then sold to pharmacists and healthcare facilities. In distribution, Flexion Therapeutics relies on close collaboration with physicians and other healthcare professionals to promote its products and effectively market its solutions for pain conditions. The company has a sales team that works closely with customers to understand their needs and offer tailored solutions. One of Flexion Therapeutics' products is Zilretta, a long-acting knee joint steroid used for pain treatment and improving mobility. Zilretta is the first of its kind on the market and has demonstrated high efficacy and safety in clinical studies. It is an important component of pain treatment for patients with osteoarthritis and other knee conditions. The company also has other products in its pipeline for pain therapy, including FX201 for the treatment of inflammation and pain in joint diseases and FX301 for the treatment of post-operative pain. These drugs are currently in development and have shown promising results in preclinical studies. While Flexion Therapeutics focuses on pain treatment, the company goes beyond that and strives to improve the lives of people suffering from pain. It is committed to developing medication solutions that not only relieve pain but also improve mobility and quality of life. With its focus on research and development, production, and distribution, the company has the resources and expertise to drive its mission and provide groundbreaking pain treatment solutions.

Flexion Therapeutics keert een dividend van 0 USD uit, verdeeld over betalingen per jaar.

De dividend kan momenteel niet worden berekend voor Flexion Therapeutics of het bedrijf keert geen dividend uit.

De ISIN van Flexion Therapeutics is US33938J1060.

Het WKN van Flexion Therapeutics is A1XEDR.

De ticker van Flexion Therapeutics is FLXN.

Binnen de laatste 12 maanden betaalde Flexion Therapeutics een dividend van . Dit komt overeen met een dividendrendement van ongeveer . Voor de komende 12 maanden zal Flexion Therapeutics naar verwachting een dividend van 0 USD betalen.

De dividendrendement van Flexion Therapeutics is momenteel .

Flexion Therapeutics betaalt elk kwartaal een dividend uit. Dit wordt uitgekeerd in de maanden .

Flexion Therapeutics betaalde de afgelopen 0 jaar elk jaar dividend.

Voor de komende 12 maanden wordt een dividend van 0 USD verwacht. Dit komt overeen met een dividendrendement van 0 %.

Flexion Therapeutics wordt toegewezen aan de sector 'Gezondheid'.

Om het laatste dividend van Flexion Therapeutics van 28-9-2024 ter hoogte van 0 USD te ontvangen, moest je het aandeel voor de ex-datum op 28-9-2024 in je portefeuille hebben.

De laatste dividenduitkering vond plaats op 28-9-2024.

In het jaar 2023 heeft Flexion Therapeutics 0 USD aan dividenden uitgekeerd.

De dividenden van Flexion Therapeutics worden in USD uitgekeerd.